Skip to main content
. 2022 Fall;40(4):413–424. doi: 10.2337/cd21-0056

FIGURE 3.

FIGURE 3

Patient case study before and after use of faster aspart in insulin pump therapy. (A) Dexcom Clarity CGM report showing glucose management indicator (GMI), average glucose, and SD. GMI improved from 8.5 to 7.0%, matching the improvement in A1C. The sensor glucose average decreased from 216 to 155 mg/dL, and the SD decreased from 74 to 47 mg/dL. (B) Dexcom Clarity CGM ambulatory glucose report and glucometrics comparison between pre- and post-adoption of faster aspart. Sensor glucose average, SD, and coefficient of variation improved with faster aspart use. TIR improved from 33 to 70.4% on faster aspart. Time in hypoglycemia did not change overall; time in hyperglycemia >180 mg/dL [10.0 mmol/L] and >250 mg/dL [13.9 mmol/L] decreased from 66.2 and 30.1% to 28.9 and 2.8%, respectively. (C) Comparison of postmeal glycemic fluctuation between pre- and post-use of faster aspart. Postprandial glucose fluctuations were reduced with faster aspart use.